Application of atractylenolide III in preparation of medicine for preventing and treating liver injury caused by cis-platinum
By using Atractylodes lactide III to inhibit the expression of chemokines and antimicrobial peptide factors in liver tissues, drugs to prevent and treat liver damage caused by cisplatin were prepared, and the problem of ineffective treatment of cisplatin liver damage in the prior art was solved, and hepatotoxicity was significantly reduced and improves treatment safety and cost-effectiveness.
Patent Information
- Application Number
- CN202411494660.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-24
- Publication Date
- 2024-11-22
AI Technical Summary
There is no effective therapeutic drug in the prior art that can reduce its toxicity to the liver without affecting the anti-tumor activity of cisplatin, resulting in the problem of liver damage caused by cisplatin.
Drugs with Atractylodes lactone III as the main component are prepared by inhibiting the expression of chemokines and antimicrobial peptide factors in damaged liver tissues. Atractylodes lactone III accounts for 1 in total mass. ~99%, combined with appropriate pharmaceutical excipients, dosage forms include various forms such as granules, tablets, etc.
Atractylodes lactide III significantly reduces liver damage caused by cisplatin, reduces hepatotoxicity, improves the safety of cancer treatment, and reduces treatment costs, providing a new auxiliary treatment idea.
Smart Images

Figure CN118986963A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medicine-related aspects, and particularly relates to the application of atractylodes lactone III in the preparation of a drug for preventing and treating liver damage caused by cisplatin. Background Art
[0002] Cisplatin is widely used to treat various solid tumors, including head and neck cancer, cervical cancer, ovarian cancer, prostate cancer, testicular cancer and colorectal cancer. Its mechanism of action is simply that cisplatin interacts with the purine bases of cancer cell DNA, preventing its replication, stopping its biological functions, and ultimately inhibiting the growth of these malignant cells. However, cisplatin is a "double-edged sword". While fighting cancer, it has toxic effects on multiple tissues, such as the liver, kidneys and heart. The liver is the main site for most metabolic reactions. After entering the human body, cisplatin enters cells through passive transport, quickly diffuses into various tissues, and accumulates in the liver, so the concentration is high. Cisplatin is biotransformed in the liver by a complex of cytochrome P450 enzymes, which is the main enzyme involved in hepatotoxicity, leading to liver dysfunction, mainly manifested as increased levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), hepatocyte necrosis and internal structural lesions of liver tissue. Liver injury mainly includes chemical liver injury, alcoholic liver injury, immune liver injury and drug liver injury, and liver injury caused by cisplatin belongs to drug liver injury.
[0003] In recent years, experts and scholars have been committed to reducing liver damage caused by cisplatin, but there is no specific therapeutic drug so far. Currently, supportive therapies such as changing the administration time, administration speed, and administration route are mainly used to alleviate liver damage caused by cisplatin, but the effect is limited. Therefore, a drug that does not affect the anti-tumor activity of cisplatin and can reduce liver toxicity is urgently needed to be discovered.
[0004] Atractylodes macrocephala is one of the famous "eight flavors of Zhejiang" authentic medicinal materials. It was first recorded in "Shennong's Herbal Classic" and was listed as a top-grade product. It is known as "Northern Ginseng and Southern Atractylodes" among the people. Atractylodes macrocephala is used as medicine with dried rhizomes. It is warm in nature, sweet and bitter in taste, and belongs to the spleen and stomach meridians. It has the effects of strengthening the spleen and replenishing qi, drying dampness and promoting diuresis, stopping sweating, and calming the fetus. It is known as "ten medicines and nine Atractylodes" in traditional Chinese medicine prescriptions. It is mainly used clinically to treat symptoms such as spleen deficiency, poor appetite, diarrhea, and loose stools. Its immune regulation effect is particularly prominent. Atractylodes macrocephala contains a variety of medicinal ingredients such as sesquiterpenoid volatile oil substances and polysaccharides. Among them, atractylodes lactone compounds are the main active ingredients of Atractylodes macrocephala. Atractylodes lactones mainly include atractylodes lactone I, atractylodes lactone II, and atractylodes lactone III. Atractylodes lactones have significant anti-tumor activity, among which the relevant research on atractylodes lactone I is the most comprehensive. In addition to its anti-tumor activity, atractylodes lactone III also has neuroprotective effects, immunomodulatory and anti-inflammatory activities. Studies have shown that chemokines and antimicrobial peptide factors are related to hepatotoxicity and are significantly upregulated in liver injury tissues. The present study found that Atractylodes lactone III can significantly reduce the high expression of chemokines such as Cxcl1 and antimicrobial peptide factors such as S100a8 in liver injury tissues caused by cisplatin. Therefore, if Atractylodes lactone can reduce the hepatotoxicity of cisplatin without affecting its anti-tumor activity, it will be a very good source of drugs for preventing and treating liver injury caused by cisplatin. Summary of the invention
[0005] The purpose of the present invention is to provide the use of atractylodes lactone III in the preparation of a drug for preventing and treating cisplatin-induced liver injury, so as to solve the problem that there is no specific therapeutic drug for cisplatin-induced liver injury mentioned in the above background technology.
[0006] To achieve the above object, the present invention provides the following technical solutions: The application of atractylodes lactone III in the preparation of a drug for preventing and treating liver injury caused by cisplatin is as follows: The dosage of Atractylodes lactone III in mice for the prevention and treatment of cisplatin-induced liver injury is 20 mg / kg / d; Prevention and treatment of cisplatin-induced liver injury is achieved by inhibiting the expression of chemokines and antimicrobial peptide factors in damaged liver tissue; Chemokines and antimicrobial peptide factors include Cxcl1 and S100a8; Drugs for preventing and treating cisplatin-induced liver injury include atractylodes lactone III and pharmaceutical excipients; In the drug for preventing and treating liver injury caused by cisplatin, atractylodes lactone III accounts for 1 to 99% of the total weight.
[0007] Preferably, pharmaceutical excipients include but are not limited to diluents.
[0008] Preferably, the dosage forms of the drug for preventing and treating liver injury caused by cisplatin include granules, tablets, powders, capsules, oral liquids, injections, sprays, aerosols, powder sprays, emulsions, nasal drops, suppositories, pills, microsphere preparations and tinctures.
[0009] Preferably, the purity of the raw material of Atractylodes lactone III used in the drug for preventing and treating liver damage caused by cisplatin is greater than 90%.
[0010] Compared with the prior art, the present invention provides the use of Atractylodes macrocephala lactone III in the preparation of a drug for preventing and treating liver damage caused by cisplatin, which has the following beneficial effects: (1) The present invention confirms that Atractylodes lactone III can be used to prevent and treat liver damage caused by cisplatin, providing a new idea for the adjuvant treatment of cancer.
[0011] (2) Atractylodes lactone III in the present invention is highly effective and has abundant sources, which can greatly reduce the toxic side effects of cisplatin on the liver during cancer treatment and significantly reduce treatment costs. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] The accompanying drawings are used to provide a further understanding of the present invention and constitute a part of the specification. Together with the embodiments of the present invention, they are used to explain the present invention and do not constitute a limitation of the present invention. In the accompanying drawings: Figure 1 It is the structural diagram of atractylodes lactone Ⅰ, atractylodes lactone Ⅱ and atractylodes lactone Ⅲ; Figure 2 is the experimental data graph, Figure 2 The changes in mouse body weight during the construction of the liver injury animal model in A. Figure 2 The organ coefficient of B mice in the experiment; Figure 3 Changes in the content of each component in mouse serum, Figure 3 A in the figure represents the change of GOT content in mouse serum during the construction of the animal model of liver injury. Figure 3 B in the figure is the change in GPT content. Figure 3 C in the equation is the change in CAT content and Figure 3 D in is the change of GSH content; Figure 4 Liver sections of mice in the control group, model group, and Atractylodes lactone III group (H&E); Figure 5 The expression of Cxcl1 and S100a8 factors in liver tissue of mice in the control group, model group and Atractylodes lactone Ⅲ group. Figure 5 A in the middle is a schematic diagram of the expression of S100a8 factor. Figure 5 B in the figure is a schematic diagram of the expression of Cxcl1 factor; Figure 6 The expression of Cxcl10 and S100a9 factors in liver tissue of mice in the control group, model group and Atractylodes lactone Ⅲ group. Figure 6 A in the middle is the expression of S100a9 factor, Figure 6 Middle B shows the expression of Cxcl10 factor. DETAILED DESCRIPTION
[0013] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0014] See also Figures 1 to 6 , the present invention provides a technical solution: The application of atractylodes lactone III in the preparation of a drug for preventing and treating liver injury caused by cisplatin is as follows: Among the drugs for preventing and treating cisplatin-induced liver injury, the purity of the raw material of Atractylodes lactone III is greater than 90%, and the dosage for mice is at least 20 mg / kg / d (equivalent to at least 133.19 mg / kg / d for humans). Its function in preventing and treating cisplatin-induced liver injury is achieved by inhibiting the expression of chemokines and antimicrobial peptide factors (Cxcl1, Cxcl10, S100a8, and S100a9) in damaged liver tissue. Prevention and treatment of cisplatin-induced liver injury is achieved by inhibiting the expression of chemokines and antimicrobial peptide factors in damaged liver tissue; Chemokines and antimicrobial peptide factors include Cxcl1 and S100a8; Drugs for preventing and treating cisplatin-induced liver injury include atractylodes lactone III and pharmaceutical excipients; In the drug for preventing and treating liver injury caused by cisplatin, atractylodes lactone III accounts for 1 to 99% of the total weight.
[0015] Pharmaceutical excipients include, but are not limited to, diluents.
[0016] The dosage forms of drugs for preventing and treating cisplatin-induced liver injury include granules, tablets, powders, capsules, oral solutions, injections, sprays, aerosols, powder sprays, emulsions, nasal drops, suppositories, pills, microsphere preparations and tinctures.
[0017] The purity of the raw material of Atractylodes lactone III used in the drug for preventing and treating liver damage caused by cisplatin is greater than 90%.
[0018] A use of atractylodes lactone III in the preparation of a drug for preventing and treating liver damage caused by cisplatin. Atractylodes lactone III has a significant effect in alleviating liver damage caused by cisplatin: The structural formula of Atractylodes lactone III is as follows:
[0019] The pharmacological experiments of the present invention show that Atractylodes lactone III has no significant effect on the body weight and organ coefficient of mice and has high safety; it can significantly reduce the significant increase of ALT and AST levels in serum caused by cisplatin; it can significantly restore the significant decrease of CAT and GSH levels in serum caused by cisplatin; it can alleviate the inflammatory infiltration of liver tissue caused by cisplatin; and it can significantly downregulate the high expression of chemokines Cxcl1, Cxcl10 and antimicrobial peptide factors S100a8, S100a9 caused by cisplatin.
[0020] The establishment and grouping of the mouse model of cisplatin-induced drug liver injury are as follows: Instruments and Equipment Zeiss stereo microscope; low-temperature centrifuge; -80℃ refrigerator; fluorescence quantitative PCR instrument; ALT, AST, CAT and GSH detection kits; Atractylodes lactone I, Atractylodes lactone II and Atractylodes lactone III; cisplatin injection.
[0021] Mouse source SPF-grade healthy and mature 6-8 week-old Balb / c male mice were purchased and grouped after 1 week of adaptive feeding.
[0022] Model building and grouping Mice were randomly divided into 5 groups: control group, model group (cisplatin 20 mg / kg), atractylodes lactone I (20 mg / kg), atractylodes lactone II (20 mg / kg), and atractylodes lactone III (20 mg / kg). Atractylodes lactone was dissolved with 0.5% sodium carboxymethylcellulose (CMC-Na). Cisplatin injection was diluted with normal saline. Mice in the treatment group were gavaged with atractylodes lactone, and mice in the control group and model group were gavaged with 0.5% CMC-Na for 7 days. Then, the control group was intraperitoneally injected with normal saline, and the model group and treatment group were intraperitoneally injected with cisplatin injection. After 48 hours, the mice were killed by carbon dioxide asphyxiation.
[0023] Observation of general condition of mice Observe the overall condition and activity of the animals and pay attention to the weight changes of the mice. After killing the mice by carbon dioxide asphyxiation, they were quickly dissected and the weight of the internal organs was weighed. The organ coefficient was calculated as the weight of the mouse organ / body weight × 100%.
[0024] Pathological observation of mouse liver tissue Mouse livers were fixed with 4% paraformaldehyde, embedded in paraffin, and routinely sectioned. Histopathological changes were observed under an optical microscope after hematoxylin and eosin (H&E) staining.
[0025] Detection of related indicators in mouse serum 1.5 mL of blood was collected by eyeball removal, centrifuged at 3500 rpm for 10 min, and stored at -80°C for later use. ALT, AST, CAT and GSH detection kits were then used for content detection. The determination was performed according to the instructions of the detection kits.
[0026] Expression of antimicrobial peptide factors in mouse liver tissue Weigh 40 mg of tissue sample accurately into a 1.5 mL centrifuge tube containing 4 sterile steel beads, add 1 mL of RNAiso Plus reagent, and grind at 70 Hz for 3 min in a pre-cooled homogenizer to obtain tissue homogenate. Total RNA was extracted and reverse transcribed, and the obtained cDNA was used for subsequent experiments.
[0027] The reagents were mixed for fluorescence quantitative PCR experiment. The primer sequences were shown in Table 1. GAPDH was used as the internal standard. 2 -△△CT Method to measure gene expression.
[0028] Table 1 Primer sequences Gene Sequence (5'-3') GAPDH F (SEQ ID NO.1) AGGTCGGTGTGAACGGATTTG GAPDH R (SEQ ID NO.2) TGTAGACCATGTAGTTGAGGTCA S100a8 F (SEQ ID NO.3) ATCCTTTGTCAGCTCCGTCTT S100a8 R (SEQ ID NO. 4) TCTCCAGTTCAGACGGCATT Cxcl1 F (SEQ ID NO.5) AAGGTGTCCCCAAGTAACGG Cxcl1 R (SEQ ID NO.6) TGTTGTCAGAAGCCAGCGTT Cxcl10 F (SEQ ID NO. 7) TGAGAGACATCCCGAGCCAA Cxcl10 R (SEQ ID NO. 8) GAGGCAGAAAATGACGGCAG S100a9 F (SEQ ID NO.9) TGGCCAACAAAGCACCTTCT S100a9 R (SEQ ID NO.10) GTCAGGGTGTCCTTCCTTCC Statistical methods All statistical analyses were performed using SPSS, Origin, and AI software. One-way analysis of variance (ANOVA) was used for multiple group comparisons. Data were expressed as the mean ± standard deviation (SD) of the number of independent experiments. P < 0.05 was considered statistically significant.
[0029] Example 1 The model was constructed according to the above method, and after the administration, the general condition of mice in each group was observed; The feeding and activity of mice in each group were normal. After the injection of cisplatin, the weight of mice decreased significantly. There was a significant difference in weight between the control group and the model group. Two mice died in the model group, four died in the atractylodes lactone I group, two died in the atractylodes lactone II group, and no one died in the atractylodes lactone III group and the control group. The organ coefficient results showed that atractylodes lactone III had no significant effect on various organs ( Figure 2 ). Although the organ coefficient results of Atractylodes lactones I and II also had no significant effect, the premise was that mice had already died. The organ coefficients of surviving mice without significant differences cannot explain their safety. Based on the survival rate of mice, the applicant believes that Atractylodes lactone III has higher safety.
[0030] Example 2 The model was constructed according to the above method, and after the administration was completed, the relevant indicators in the serum were detected; The results showed that Atractylodes lactone could significantly reduce the significant increase in ALT and AST levels caused by cisplatin; it could significantly restore the significant decrease in CAT and GSH levels in serum caused by cisplatin ( Figure 3, *, # represent P<0.05, **, ## represent P<0.01). Among them, the large error in AST levels of Atractylodes lactones I and II was caused by the death of mice during the experiment and the reduction in the number of repetitions. In addition, the ALT level of Atractylodes lactone II also had a large error for the same reason. Based on the above results, it was found that Atractylodes lactone III had a more significant function in alleviating cisplatin-induced drug-induced liver injury, so Atractylodes lactone III was selected for subsequent research.
[0031] Gsh is glutathione peroxidase, AST is aspartate aminotransferase, ALT is alanine aminotransferase, and CAT is catalase; CON was the control group, CAT was the model group, ATⅠ was atractylodes lactone 1, ATⅡ was atractylodes lactone 2, and ATⅢ was atractylodes lactone 3.
[0032] Example 3 The model was constructed according to the above method, and liver tissue pathology was observed after drug administration; The liver lobule structure of the control group was clear, and the hepatocytes were arranged in rows; the liver tissue of the model group showed large areas of watery degeneration, punctate necrosis of hepatocytes, disordered arrangement of hepatic cords, and severe inflammatory infiltration; the inflammatory infiltration of the liver tissue of the Atractylodes lactone III group was alleviated, and the hepatocytes were slightly edematous ( Figure 4 ). This indicates that Atractylodes macrolide III can significantly alleviate drug-induced liver injury caused by cisplatin.
[0033] Example 4 The model was constructed according to the above method, and after administration, the expression of chemokines and antimicrobial peptide factors in liver tissue was detected; The results showed that Atractylodes lactone III could significantly downregulate the high expression of chemokines Cxcl1, Cxcl10 and antimicrobial peptide factors S100a8 and S100a9 induced by cisplatin ( Figure 5 , Figure 6 **, ## represents P<0.01), indicating that Atractylodes lactone III can significantly alleviate drug-induced liver injury caused by cisplatin.
[0034] It can be seen from the above examples that Atractylodes lactone III has a significant technical effect in preventing and treating liver damage caused by cisplatin.
[0035] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. The use of Atractylodes macrocephala lactone III in the preparation of a drug for preventing and treating liver damage caused by cisplatin, characterized in that: The application method is as follows: The dosage of atractylodes lactone III in mice for the prevention and treatment of cisplatin-induced liver injury is 20 mg / kg / d; Prevention and treatment of cisplatin-induced liver injury is achieved by inhibiting the expression of chemokines and antimicrobial peptide factors in damaged liver tissue; Chemokines and antimicrobial peptide factors include Cxcl1 and S100a8; Drugs for preventing and treating cisplatin-induced liver injury include atractylodes lactone III and pharmaceutical excipients; In the drug for preventing and treating liver injury caused by cisplatin, atractylodes lactone III accounts for 1 to 99% of the total weight.
2. The use of Atractylodes macrocephala lactone III according to claim 1 in the preparation of a drug for preventing and treating liver damage caused by cisplatin, characterized in that: Pharmaceutical excipients include diluents.
3. The use of Atractylodes macrocephala lactone III according to claim 1 in the preparation of a drug for preventing and treating liver damage caused by cisplatin, characterized in that: The dosage forms of drugs for preventing and treating cisplatin-induced liver injury include granules, tablets, powders, capsules, oral solutions, injections, sprays, aerosols, powder sprays, emulsions, nasal drops, suppositories, pills, microsphere preparations and tinctures.
4. The use of Atractylodes macrocephala lactone III according to claim 1 in the preparation of a drug for preventing and treating liver damage caused by cisplatin, characterized in that: The purity of the raw material of Atractylodes lactone III used in the drug for preventing and treating liver damage caused by cisplatin is greater than 90%.
Citation Information
Patent Citations
Application of atractylenolide III in preparation of anti-hepatic fibrosis drugs
CN113797194A
Cited By
Use of atractylodes lactone III in preparing a medicine for improving transplantation of frozen-thawed ovarian tissue
CN122768240A
